Recent Company News

• 05:51 PM ET May 07, 2025
  

  FDA grants orphan drug designation to Sema3A for Alport syndrome (€23.44, 0.00)

• 01:37 AM ET May 07, 2025
  

  Evotec awarded $2.5M grant by the Gates Foundation to generate next generation tuberculosis treatments (€7.29, 0.00)

• 04:04 AM ET May 06, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:58 AM ET Apr 24, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:11 AM ET May 06, 2025
  

  Evotec reports Q1 adjusted EBITDA €3.1M vs year-ago €7.8M (€7.48, 0.00)

• 05:22 PM ET Apr 24, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:42 AM ET Apr 24, 2025
  

  Evotec upgraded to hold from sell at Deutsche Bank (€7.22, 0.00)

• 01:41 AM ET Apr 24, 2025
  

  Evotec reports significant progress in strategic protein degradation collaboration with Bristol Myers Squibb triggering $75M milestone payments (€7.22, 0.00)

• 09:19 AM ET Apr 17, 2025
  

  StreetAccount Summary - US Pre-market trading update